Shenzhen Aisin Dawei Pharmaceutical Technology

Shenzhen Aisin Dawei Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in Shenzhen, China, specializing in the discovery and development of precision anti-cancer small molecule drugs. The company leverages its proprietary technology platform to develop targeted prodrugs that are selectively activated by specific enzymes, such as AKR1C3, which are highly expressed in tumor tissues. This approach is designed to enhance the efficacy of potent cytotoxic agents while significantly reducing systemic side effects. Its lead program, AST-001, is currently undergoing Phase 2 clinical trials for hepatocellular carcinoma and has shown potential in other AKR1C3-overexpressing solid tumors. Aisin Dawei's pipeline also includes several other candidates in various stages of development targeting different tumor microenvironment characteristics. The company is backed by prominent Chinese venture capital firms and continues to expand its oncology portfolio through internal R&D.